Each enteric coated tablet contains Aspirin BP 75 mg.
Aspirin has an antithrombotic action, mediated through inhibition of platelet activation, which has been shown to be useful in secondary prophylaxis following myocardial infarction and in patients with unstable
angina or cerebral transient ischemic attacks.
DOSAGE AND ADMINISTRATION:
150 mg at diagnosis and 75 mg daily thereafter.
CONTRAINDICATION AND PRECAUTION:
Hypersensitivity to aspirin, hypoprothrombinaemia, haemophilia and peptic ulceration.
Salicylates may enhance the effects of anticoagulants, oral hypoglycaemic,
phenytoin, probenecid and may increase the toxicity of sulphonamides.
These may also precipitate bronchospasm or induce attacks of asthma in
Patients using enteric-coated aspirin should be advised against ingesting
antacids simultaneously, to avoid premature drug release.
Salicylates may induce hypersensitivity, asthma, urate kidney stones, chronic
gastro-intestinal blood loss, tinnitus, nausea and vomiting. The special
coating of aspirin helps to reduce the incidence of side-effects resulting
from gastric irritation.
Aspirin is generally contraindicated in patients taking oral anticoagulants
because of the risk of bleeding.
USE IN PREGNANCY AND LACTATION:
Aspirin does not appear to have teratogenic effects. However, prolonged
pregnancy and labour, with increased bleeding before and after delivery,
decreased birth weight and increased rate of stillbirth were reported with
high blood salicylate levels. Aspirin should be avoided during the last 3
months of pregnancy.
As aspirin is excreted in breast milk, it should not be used by patients who
are breast feeding.
Store below 30˚C. Keep all medicines out of the reach of children.